SCHEMBL3560176

SCHEMBL3560176

COc1ncc(-c2cccnc2F)c(OC)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 1/20 0.42
QPCTL Q9NXS2 1/20 0.42
CYP1A2 P05177 1/20 0.41
METAP2 P50579 1/20 0.41
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA2 P47869 1/20 0.38
PTGES2 Q9H7Z7 1/20 0.38
HKDC1 Q2TB90 1/20 0.37
PADI1 Q9ULC6 1/20 0.37
PADI3 Q9ULW8 1/20 0.37
PADI4 Q9UM07 1/20 0.37
PADI2 Q9Y2J8 1/20 0.37
ATG4B Q9Y4P1 1/20 0.37
CRHR1 P34998 1/20 0.36
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
PDE2A O00408 3/20 0.36
PDE10A Q9Y233 3/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565523 0.82 QPCT (0.42) QPCTQPCTLCYP1A2METAP2GABRG2
SCHEMBL15196011 0.79 PDE10A (0.39) GABRG2GABRB3GABRA2ALOX5APFEN1
SCHEMBL3562325 0.79 QPCT (0.42) QPCTQPCTLCYP1A2METAP2GABRG2
SCHEMBL3557693 0.78 USP8 (0.43) QPCTQPCTLCYP1A2METAP2GABRG2
SCHEMBL30961410 0.77 QPCT (0.44) QPCTQPCTLCYP1A2METAP2GABRG2
SCHEMBL3564444 0.76 QPCT (0.45) QPCTQPCTLCYP1A2METAP2GABRG2
SCHEMBL943863 0.76 PLAU (0.47) QPCTQPCTLCYP1A2METAP2GABRG2
SCHEMBL3567107 0.76 CYP1A2 (0.44) QPCTQPCTLCYP1A2METAP2GABRG2
SCHEMBL3565802 0.76 QPCT (0.42) QPCTQPCTLCYP1A2METAP2CRHR1
SCHEMBL30513063 0.76 QPCT (0.42) QPCTQPCTLCYP1A2METAP2GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007750-B1 AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LTD (GB) 2013-08-21 EP disclosed
US-7727988-B2 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2010-06-01 US disclosed
US-7727988-B2 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2010-06-01 US disclosed
US-7727988-B2 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2010-06-01 US disclosed
EP-2007750-A1 AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2008-12-31 EP disclosed
US-20070249642-A1 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2007-10-25 US disclosed
US-20070249642-A1 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2007-10-25 US disclosed
US-20070249642-A1 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2007-10-25 US disclosed
WO-2007113232-A1 AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2007-10-11 WO disclosed
WO-2007113232-A1 AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249642-A1 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione AZI2, NT5C3B, CYP1B1 QPCT 2929/4885QPCTL 3866/4885CYP1A2 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.